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Background: The administration of short-acting opioids before emergence is useful for preventing emergence cough 
induced by an endotracheal tube. This study examined the clinically effective dose of alfentanil for suppressing cough 
during emergence from desflurane anesthesia. 
Methods: Twenty-nine adult patients undergoing elective oral surgery were enrolled in this study. During emergence 
from anesthesia, the patients received alfentanil diluted in 10 ml normal saline when the end-tidal vol% of desflurane 
decreased to 3%. The initial alfentanil dose was 16 μg/kg. The alfentanil dose for consecutive patients, determined by 
Dixon’s up-and-down method, increased or decreased by 2 μg/kg according to a previous patient’s result. 
Results: The 50% effective dose (ED50) of alfentanil for suppressing cough during emergence from desflurane 
anaesthesia was 9.3 ± 1.5 μg/kg according to Dixon’s up-and-down method. Isotonic regression revealed an ED50 
and ED95 (95% confidence interval) of alfentanil 10.0 μg/kg (6.8-13.2 μg/kg) and 14.0 μg/kg (7.7-19.4 μg/kg), 
respectively.
Conclusions: The ED95 of alfentanil for suppressing emergence cough was 14.0 μg/kg. A single bolus administration 
of alfentanil during emergence from anesthesia was useful for suppressing emergence cough. (Korean J Anesthesiol 
2011; 61: 292-296)
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Introduction
Endotracheal tube-induced coughing during emergence 
from general anesthesia is a common phenomenon with a 
reported incidence of 38-96% [1-3]. Emergence cough is 
associated with an increase in heart rate, blood pressure, 
intracranial, intraocular, and intra-abdominal pressure. These 
adverse effects can result in coronary ischemia, arrhythmia 
or wound dehiscence [4-6]. Several techniques or drugs have 
been investigated to prevent emergence cough, such as deep 
extubation [7], a change to laryngeal mask during emergence 
[8], topical or intracuff lidocaine application [9,10] and the 
administration of dexmedetomidine [11] or short-acting 
opioids [12-14]. The beneficial effects of short-acting opioids, 
such as alfentanil or remifentanil, for suppressing cough 
during emergence have been reported. However, there is no 
data on the optimal dose of alfentanil to prevent cough during 
emergence. This study examined the clinically effective single-
dose of alfentanil for suppressing cough during emergence from 
desflurane anesthesia.
Materials and Methods
This study was approved by the institutional review board 
and written informed consent was obtained from the subjects. 
ASA I-II adult patients undergoing elective oral surgical pro-
cedures were enrolled in this study. The exclusion criteria 
included treatment with antitussives or angiotensin converting 
enzyme inhibitor, a history of chronic cough, asthma or 
recent respiratory tract infections. Obese patients (body mass 
index (BMI) >30 kg/m
2) and patients with predicted difficult 
intubation were also excluded.
Thirty minutes before the induction of anesthesia, all patients 
were pre-medicated with intramuscular glycopyrrolate 0.2 
mg and midazolam 2 mg. Upon arrival at the operating room, 
routine anesthesia monitoring including ECG, pulse oximetry, 
non-invasive arterial pressure, side-stream capnography were 
applied. Anesthesia was induced with alfentanil 10 μg/kg and 
propofol 2 mg/kg, intravenously. Rocuronium 0.8 mg/kg was 
injected intravenously to facilitate nasotracheal intubation. 
Reinforced tubes were used with 7.0 mm ID and 6.5 mm ID 
for men and women, respectively. The pressure of the tracheal 
cuff was maintained at 30 cm H2O throughout the procedure. 
After induction, dexamethasone 5 mg was administered 
intravenously. Anesthesia was maintained with desflurane 
4-7 vol% in 50% N2O/O2 mixture. No additional opioid was 
administered during surgery. All patients received ketorolac 30 
mg and metoclopromide 10 mg intravenously 30 min before 
the end of surgery. Neuromuscular blocking was reversed 
by pyridostigmine and glycopyrrolate 5 min before the end 
of surgery and then the administering gas concentration 
was gradually decreased. Alfentanil diluted in 10 ml normal 
saline was injected slowly for 30 s when the end-tidal vol% of 
desflurane was decreased to 3%. After surgery when the drapes 
were removed, the pharynx was suctioned gently, the vaporizer 
of desflurane was turned off and fresh gas flow was increased 
to 6 L/min in 100% oxygen. During the emergence phase, the 
patient was stimulated verbally or with gentle tactile stimulation 
on the shoulder every 20 s. From time zero, which was defined 
as a discontinuation of desflurane, the following variables were 
measured: time to the first response to the verbal command 
‘open your eyes’ , time to tracheal extubation, end-tidal desflurane 
concentration at the first response and extubation, and the grade 
of coughing episodes (0: no cough; 1: mild, single cough; 2: 
moderate, more than 1 cough lasting <5 s; 3: severe, sustained for 
more than 5 s). These values were recorded by another observer 
blinded to the alfentanil dose. Extubation was performed when 
the patient could follow verbal commands and the tidal volume 
was sufficient. The mean arterial pressure (MAP) and heart rate 
(HR) were also recorded every 2 min from time 0 to 6 min after 
extubation. The presence of postoperative nausea and vomiting 
(PONV) and the modified Aldrete score [15] 30 min after 
admission to the post anesthesia care unit (PACU) were recorded.
Alfentanil dose was determined to be 16 μg/kg for the first 
patient, referring to a previous report [12]. Cough was defined 
as a sudden contraction of the abdomen. The success of 
suppressing cough during emergence was defined as grade 0 or 
1 of any coughing episode. If cough suppression was successful, 
the alfentanil dose was decreased by 2 μg/kg in the consecutive 
patient. On the other hand, the dose was increased by 2 μg/kg 
in the consecutive patient if it failed.
Patient data was reported as the mean ± standard deviation 
(SD). Statistical analysis was performed using the SPSS package 
(SPSS 13.0 for windows, SPSS Inc, Chicago, IL). According to 
Dixon’s up-and-down method [16], the study continued until 
seven pairs of successful-failed suppressing emergence cough 
had occurred. The 50% effective dose (ED50) of alfentanil for 
suppressing cough during emergence was defined as the mean 
of the median cross-over dose. The data was also subjected to 
isotonic regression estimators to calculate the 95% effective 
dose (ED95) and the 95% confidence interval (CI). An adjusted 
response probability was easily calculated by the pooled 
adjacent-violators algorithm (PAVA) and the CI was estimated 
using a bootstrapping approach [17]. The hemodynamic 
changes during emergence were analyzed by repeated 
measures ANOVA. A P value < 0.05 was considered significant.
Results
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seven pairs of successful-failed suppressing emergence cough 
had occurred (Fig. 1). According to the success or failure in 
suppressing emergence cough, they were divided into a cough-
suppressed group and a cough-unsuppressed group. Patient 
demographic data and operative characteristics in cough-
suppressed group and cough-unsuppressed group were 
similar (Table 1). During the emergence phase, there were no 
significant differences in the response time, extubation time, 
and end tidal desflurane concentration at the response or 
extubation between the two groups. The two groups were also 
comparable with respect to the number of patients with PONV 
and the modified Aldrete score 30 min after admission to the 
PACU (Table 2). Hemodynamic changes during the emergence 
phase between the two groups were not significantly different. 
Within each group, the HR were similar compared to the 
baseline value but the MAP increased significantly after 
extubation compared to the baseline value (Fig. 2).
The ED50 of alfentanil for suppressing cough during emer-
gence from desflurane anesthesia was 9.3 ± 1.5 μg/kg according 
to Dixon’s up-and-down method (Fig. 1). Isotonic regression, 
estimated from the Pooled-adjacent-violators algorithm (PAVA) 
response rate, revealed that an ED50 and ED95 of alfentanil were 
10.0 μg/kg (95% CI 6.8-13.2 μg/kg) and 14.0 μg/kg (95% CI 
7.7-19.4 μg/kg), respectively (Fig. 3).
Discussion 
This is the first study on the dose-response of alfentanil 
for suppressing emergence cough. In this study, the ED95 of 
alfentanil for suppressing cough during emergence from 
desflurane anesthesia was 14.0 μg/kg.
Most upper airway reflex responses including the cough 
reflex have been observed in humans anesthetized lightly 
with inhalational anesthetics [18,19]. During emergence from 
inhalational anesthesia, stimulation of the airway mucosa 
in the state of light anesthesia can cause cough responses, 
interfering with smooth emergence. Among these airway reflex 
responses, the cough reflex appears to be most vulnerable to 
the depressant effect of fentanyl [20]. Opioid agonists, such as 
fentanyl, are centrally acting antitussive agents [21]. Recent 
studies reported that the antitussive effects of opioids are 
Table 1. Demographic Data and Surgical Characteristics
Cough-
suppressed 
patients (n=16)
Cough-
unsuppressed 
patients (n=13)
Age (yr)
Gender (male/female)
Weight (kg)
ASA physical status (I/II)
History of smoking
Type of operation
  Contouring surgery
  Open reduction and internal 
    fixation of mandible 
  Cyst enucleation
  Mass excision
Duration of operation (min)
31 ± 14
9/7
60 ± 9
15/1
7
2
10
2
2
132 ± 33
32 ± 13
8/5
62 ± 8
11/2
7
0
10
2
1
124 ± 25
Data is reported as the mean ± SD or numbers. No significant 
difference between the two groups.
Table 2. Data on Coughing and Recovery Profile
Cough-suppressed patients (n=16) Cough-unsuppressed patients (n=13)
Number of coughing episode
Response time (min)
End-tidal desflurane at first response (%)
Extubation time (min)
End-tidal desflurane at extubation (%)
Aldrete score 30 min after PACU admission
Total number of patients with PONV
0 (0-2)
6.2 ± 2.1
0.67 ± 0.17
8.4 ± 1.9
0.57 ± 0.20
9.6 ± 0.5
1
2 (1-3)
6.7 ± 1.5
0.59 ± 0.17
8.4 ± 1.4
0.53 ± 0.17
9.8 ± 0.4
3
Data is reported as the mean ± SD or numbers. Number of coughing episodes is shown as the median (range). No difference between two 
groups except for the number of coughing episodes. PACU: post anesthesia care unit, PONV: postoperative nausea and vomiting.
Fig. 1. Success or failure of suppressing coughing during emergence 
from desflurane anaesthesia on the determined alfentanil dose. The 
mean ± SD of the median alfentanil dose of seven success-failure 
pairs is 9.3 ± 1.5 μg/kg.295 www.ekja.org
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mediated predominantly by mu-and kappa-opioid receptors in 
the central nervous system [22,23]. 
Several studies reported that short-acting opioids, such 
as alfentanil and remifentanil, suppressed emergence cough 
induced by the endotracheal tube. The continuous infusion 
of low-dose remifentanil during emergence from isoflurane 
anesthesia reduced the incidence and severity of emergence 
cough [13]. Lee et al. [14] found that the EC95 of the effect site 
concentration of remifentanil to prevent coughing at emergence 
from propofol-remifentanil anesthesia was 2.14 ng/ml. 
However, a bolus of 1 μg/kg remifentanil at the end of surgery 
did not reduce the incidence of cough during emergence from 
isoflurane anesthesia [24]. On the other hand, a single bolus 
injection of alfentanil (15 μg/kg) during emergence decreased 
the incidence of emergence cough from 82% to 6% [12]. For 
this reason, alfentanil may be more suitable for single bolus 
administration to decrease emergence cough. Alfentanil bolus 
administration is a simple method compared to remifentanil 
continuous infusion. However, no dose-finding study on the 
clinical effective dose of alfentanil to suppress emergence 
cough have been conducted. Therefore, the clinically effective 
single dose of alfentanil for suppressing emergence cough was 
determined using Dixon’s up-and-down method in this study. 
A single bolus administration of alfentanil at the end of 
surgery did not prolong the extubation time compared to the 
control group [12]. Similarly, the extubation time in this study 
after the administration of alfentanil was <10 min in both 
groups, which is a clinically acceptable emergence time. In the 
hemodynamic changes during emergence, HR was relatively 
stable but the MAP increased significantly after extubation in 
both groups. These results were on various doses of alfentanil. 
Therefore, more studies of the recovery profile or hemodynamic 
changes on this optimal alfentanil dose are required. 
These results have some limitations when applied to clinical 
practice. The desflurane used in this study has a direct effect 
on pungency and airway irritability [25]. This property of 
desflurane can affect the effective clinical dose of alfentanil 
for suppressing cough during emergence. The optimal dose of 
alfentanil may be different in preventing emergence cough for 
other anesthetics, such as sevoflurane or propofol. In addition, 
the criterion of success in suppressing emergence cough was 
not absence of cough. Therefore, the alfentanil dose proposed in 
this study may not be sufficient for situations requiring absolute 
smooth emergence. 
In conclusion, the 95% effective dose (ED95) of alfentanil 
for suppressing cough during emergence from desflurane 
anesthesia is 14 μg/kg using Dixon’s up-and-down method and 
Fig. 2. Hemodynamic changes during the emergence phase. Time 0: at discontinuation of desflurane, time 1: 4 min before extubation, time 
2: 2 min before extubation, time 3: at extubation, time 4: 2 min after extubation, time 5: 4 min after extubation, time 6: 6 min after extubation. 
There was no significant differences between the two groups. *P < 0.05 compared to the baseline.
Fig. 3. Pooled-adjacent-violators algorithm (PAVA) response rate. 
The ED50 and ED95 (95% confidence interval), which were estimated 
from the PAVA response rate of the alfentanil dose for suppressing 
emergence cough from desflurane anesthesia, were 10.0 μg/kg (6.8-
13.2 μg/kg) and 14.0 μg /kg (7.7-19.4 μg /kg), respectively.296 www.ekja.org
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isotonic regression. A single bolus administration of alfentanil 
during emergence from desflurane anesthesia is useful for 
suppressing emergence cough.
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